Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets

Table 2 Druggability analysis results

Gene name	Gene type	Targeted drugs
Top 10 target genes
BCHE	Enzyme	Bicalutamide, genistein, choline, isoflurophate, hexafluorenium, demecarium bromide, echothiophate iodide, butyric acid
CDK7	Protein kinase	Lycopene, genistein, flavopiridol
DKK1	Receptor ligand	Decitabine
CCR7	GPCR	Decitabine
TPI1	Enzyme	Fluorouracil, quercetin
HSD17B2	Enzyme	NADH
HBB	Transporter	Iron-dextran complex
Angiogenesis genes: SP3 targets
TIMP3	Binding protein	Salinomycin, decitabine, sulindac, adaphostin
CAV1	Binding protein	Decitabine, progesterone, mifepristone
CALB2	Binding protein	Oxaliplatin, fluorouracil
LAMB1	Receptor ligand	Benzamidine, carebastine, anistreplase, tenecteplase
DPYD	Enzyme	Oxaliplatin, gemcitabine, docetaxel, s1(combination), capecitabine, cisplatin, fluorouracil, tegafur, carboplatin, paclitaxel, genistein, enfuvirtide, raltitrexed, amifostine, irinotecan, methotrexate, mitoguazone, uracil
Angiogenesis genes: NFκB1 targets
KDR	Receptor with enzyme activity	Epigallocatechin gallate, resveratrol, sorafenib, sunitinib, bevacizumab, sirolimus, conivaptan, zonampanel, SU6668, vatalanib, vandetanib, axitinib, cediranib, trapoxin, motesanib, E-7080, erlotinib, Ca0456456, geldanamycin
FGF13	Receptor ligand	Bicalutamide
PRRX1	Transcription factor	Alitretinoin
AOX1	Enzyme	Isovanillin, norcantharidin, NSC336628

Genes and anti-cancer drugs targeting their products were obtained using Cancer Resource and PharmGKB webtools and databases. GPCR, G-protein-coupled receptor.

ISSN: 1756-994X